Biotech Distributor BDI Pharma Launches The MERREM Commitment Program™ with AstraZeneca for Secure Access to Anti-Bacterial

 Biotech Distributor BDI Pharma Launches The MERREM Commitment Program™ with
     AstraZeneca for Secure Access to Anti-Bacterial Product MERREM® I.V.

PR Newswire

COLUMBIA, S.C., Feb. 20, 2014

COLUMBIA, S.C., Feb. 20, 2014 /PRNewswire/ --BDI Pharma today announced the
launch of The MERREM Commitment Program™ with AstraZeneca, an assurance
initiative offering customers security in product availability through
contracted access to the original, branded MERREM®I.V. from AstraZeneca.
Along with this innovative new partnership, BDI Pharma was awarded the status
of Authorized Distributor of Record (ADR) for AstraZeneca and is the sole and
exclusive distributor of contracted MERREM®I.V. in the United States.


"We are excited about this new program and what it means to the healthcare
community," stated Anthony Jackson, COO for BDI Pharma. "We are all aware
that drug shortages can be costly, unpredictable, and potentially threaten
patients' treatment. With The MERREM Commitment Program™, our customers will
have peace of mind that their institution has access to product now, and
through potential shortages of generic meropenem."

Paired with the launch of this new program, BDI Pharma is offering a
discounted introductory price on MERREM®I.V. to program participants for
orders until June 30, 2014. Interested customers are encouraged to call
800-948-9834 for more information or visit for details.

About BDI Pharma, Inc.

BDI Pharma has continuously refined the concept of niche distribution,
providing solutions beyond the traditional wholesaler model since 1995. We
operate as an extension of our partners' sales force, create demand, and move
market share with each transaction. In this regard, we maintain a highly
selective process when entering into a strategic partnership. Our approach of
serving the manufactures as well as the customers over nearly two decades has
proven successful in varied market conditions. This is further supplemented
through innovative supply solutions, extensive product knowledge, 24/7
emergency availability and urgent need delivery. An open-access resource for
reference material, educational literature, market data and online ordering,
BDI Pharma's home web page (also has become
an industry-renowned point of reference. Proprietary programs covering
comprehensive reimbursement services - and 855-BDI-CARE; and
product consignment -; round out a family of solutions
tailored to the needs of the healthcare community at large.

BDI Pharma's product portfolio includes IVIG, branded and generic specialty
pharmaceuticals, chemotherapy products, vaccines, albumin, coagulation
factors, high-titer or "hyper" immune globulins, and other specialty
injectables. BDI Pharma is recognized as an "ADR," or Authorized Distributor
of Record, for all of the manufacturers it represents.

Read more news from BDI Pharma, Inc.

Contact: Angela Phillips

SOURCE BDI Pharma, Inc.
Press spacebar to pause and continue. Press esc to stop.